The SICC Innvierte of CDTI Innovation invests together with several co-investors in Orikine Bio, a company that develops a new generation of therapies for autoimmune, inflammatory and oncological diseases

Orikine Bio, a biotechnology company founded in 2022 as a spin-off of the Centre for Genomic Regulation (CRG) in Barcelona, develops therapies that can "reprogram" the immune system, similar to how software engineers rewrite faulty code to repair computer systems.

Its Foldikine™ platform designs bispecific cytokines, molecules that send precise and targeted instructions to immune cells specifically, effectively and safely. By reprogramming these cells, they restore proper immune function, offering innovative solutions for conditions such as autoimmune diseases and chronic inflammation.

The Orikine Bio team is made up of leading experts in biotechnology, immunology, protein engineering and business development. Its main objective is to turn cutting-edge research into therapies that can rewrite the future of medicine, correcting the errors of the immune system from its root.

The CDTI Innovation, through Innvierte, has closed an investment operation in this biotechnology company with Sabadell Asabys Health Innovation Investments II, FCR; Sabadell Asabys Health Innovation Investments 2B, SCR SA and AFB Seed Fund II with an investment amount of 2.7 million euros. Thanks to this participation, the CDTI Innovation contributes to improving the health and well-being of people, promoting the development of products to accelerate the recovery of patients.
 

Asabys Partners

Asabys Partners is a venture capital firm specializing in the health sector, founded in 2018 by Josep Ll. Sanfeliu and Clara Campàs, participated by Alantra and with the support of Banc Sabadell as an anchor investor. Asabys invests in highly innovative and disruptive companies that meet unmet medical needs in bio-weapon verticals and healthcare technologies. The firm’s investment in the company comes from its vehicles Sabadell Asabys Health Innovation Investments II, FCR and Sabadell Asabys Health Innovation Investments 2B, SCR SA.
 

AdBio Partners

AFB Seed Fund II is a fund managed by AdBio partners, a European venture capital firm based in Paris and based in Barcelona, which invests in highly innovative projects. Its strategy combines extensive experience in the creation of new companies, as well as in investments in the initial phase, providing solid business support to boost the growth of the company. Created in 2016, AdBio Partners has made 28 European investments from two seed funds. These companies have raised more than €1 billion in additional capital from trade unions and international strategic funds.
 

Innvierte

Innvierte is an initiative whose objective is to promote business innovation by supporting venture capital investment in technology-based or innovative companies. This program is implemented through the closed-ended collective investment company Innvierte Economía Permanente SICC S.M.E., S.A., self-managed and subject to the supervision of the National Securities Market Commission and of which CDTI Innovation is a single shareholder.

To date, the CDTI Innovation has committed, through Innvierte, 2,885.8 M€ in 54 investment vehicles and, through its co-investment line, has directly committed an amount of 833.6 M€ in 197 companies.

Innvierte is part of the Spanish Strategy of Science, Technology and Innovation 2021-2027, approved by Agreement of the Council of Ministers, in September 2020. This Strategy contains the objectives, reforms and measures that must be adopted throughout the field of R+D+I in order to boost its growth and impact, and is one of the pillars on which the design of the Government's R+D+I policy for the coming years is based.
 

CDTI Innovation

The Center for Technological Development and Innovation, CDTI E.P.E. It is the innovation agency of the Ministry of Science, Innovation and Universities, whose objective is the promotion of technological innovation in the business environment. The mission of the CDTI is to ensure that the Spanish business fabric generates and transforms scientific and technical knowledge into globally competitive, sustainable and inclusive growth. In 2025, within the framework of the Strategic Plan 2024-2027, the CDTI provided more than 2 billion euros of support to Spanish companies and startups.
 

More information:

Press Office
press@cdti.es
91-581.55.00

On the Internet
Website: www.cdti.es
On Linkedin: https://www.linkedin.com/company/cdti/
On X: https://x.com/CDTI_innovacion
On Youtube: https://www.youtube.com/user/CDTIoficial

Orikine Bio:
Website: https://www.orikine.bio/
On LinkedIn: https://www.linkedin.com/company/orikine-bio/

Asabys Partners:
Website: https://asabys.com/
On LinkedIn: https://www.linkedin.com/company/asabys-partners/
In X: https://x.com/AsabysPartners

AdBio Partners:
Website: https://adbio.partners/
On LinkedIn: https://www.linkedin.com/company/advent-france-biotechnology/
In X: https://x.com/AdBiopartners

This content is copyright © 2026 CDTI,EPE. The use and reproduction is allowed by citing the source and digital identity of CDTI (@CDTI_innovacion).